89Bio Inc. shares rose 34%, to $6.68, after Chief Executive Rohan Palekar discussed the progress of its lead drug candidate Monday during an H.C. Wainwright conference.
Mr. Palekar detailed the "broad metabolic benefits" and favorable clinical trial results for pegozafermin. The drug is being developed for non-alcoholic steatohepatitis and severe hypertriglyceridemia.
89bio, Inc. (ETNB) shares are trading more than 36 percent on Tuesday morning continuing an uptrend since the company reported positive results from ENTRIGUE Phase 2 trial of Pegozafermin in patients with severe Hypertriglyceridemia.
https://www.marketwatch.com/story/89bio-up-after-conference-presentation-271663090966
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.